✅   Black Diamond treads water on small snapshot of Phase 2 lung cancer data

Health

Black Diamond Therapeutics’ stock price $BDTX jumped more than 15% premarket Monday morning after the company reported its first Phase 2 results for a first-line lung cancer treatment, but shares fell about 3% after the opening bell. Researchers were testing BDTX-1535 in patients with relapsed/refractory EGFR-mutant non-small cell lung cancer at two dose levels: 100 mg and 200 mg. Forty patients were sorted into cohorts based on whether they had non-classical EGFR mutations or C797S resistance mutations, Black Diamond said. As of the Aug. 17 cutoff, 22 patients who received the 200 mg dose were evaluable for efficacy, 19 of whom expressed mutations showing resistance to AstraZeneca’s Tagrisso therapy.

Endpoints     Sep 23, 2024